Question-and-Answer Session
Operator
Thank you. (Operator Instructions). And we will take our first question from Joseph Schwartz from Leerink Swann.
Joseph Schwartz – Leerink Swann Llc
Great. Good morning. Thanks for taking the question. I was wondering if you can give us an update on severe high cholesterol study, how is side activation screening going, have you started to enroll payment yet?
Stanley T. Crooke
Yes, its going very well as we don’t provide detailed information on enrollment that all of the trials with mipomersen are going well and enrolling.
Joseph Schwartz – Leerink Swann Llc
So, I think I heard you say that late this year or early next year, you expect to report a [promotion] data in other high cholesterol populations, would this include, what was called the apheresis-eligible study and can you just explain to us it that just a nuance with the name change or has the strategy with those patients changed, can you take people off of that for instance, give us some color there so we can understand that. Thanks.
Stanley T. Crooke
There hasn’t been any change in the basic design or the thrust of that trial Joe, its so I guess the right answer is it's just a name change. And I think we've said on the last cal or two that we have these four Phase III trials that we wanted to get up and running and they're getting up and running and they are enrolling nicely and we expect over the, from the middle of this year to 2010 and I don’t want to be a lot more specific than that to have sort of the rolling series of clinical trials that we will complete and we'll have those results. All geared toward having the data that we want to use to support our first filing. So, without being more specific about exactly what trial we will finish at exactly what date, I think we are feeling very good about where that program stands and that we are going to meet that guidance right on the numbers.
Joseph Schwartz – Leerink Swann Llc
Thanks.
Operator
And we will take our next question from Mark Monane from Needham.
Mark Monane – Needham & Company
Good morning and greetings from New York City. Couple of questions please. Thanks for the review for starting us off. When we look at the Phase III data, I know they haven’t come out, what kind of results do you think would be clinically relevant beyond statistically significant in these patients to make a difference in the real world?
- To read the full transcript on Seeking Alpha, click here »
